Probing and trapping a sensitive conformation: Amyloid-β fibrils, oligomers, and dimers

Journal of Alzheimer's Disease

Volumn 32, Issue 1, 2012, Pages 197-215

  Fawver, Janelle N ^a   Duong, Karen T ^a   Wise Scira, Olivia ^b   Petrofes Chapa, Rachel ^a   Schall, Hayley E ^a   Coskuner, Orkid ^b   Zhu, Xiongwei ^c   Colom, Luis V ^d   Murray, Ian V J ^a  

^a TEXAS A M COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS AT BROWNSVILLE   (United States)

Author keywords

Alzheimer's disease; amyloid; antibodies; berberine; curcumin; homotaurine; methylene blue; molecular modeling; protein folding; taurine

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; CALMIDAZOLIUM; CURCUMIN; DIMER; HOMOTAURINE; INOSITOL; METHYLENE BLUE; OLIGOMER; TAURINE;

AMINO TERMINAL SEQUENCE; ARTICLE; ELECTRON MICROSCOPY; EPITOMICS; IMMUNOBLOTTING; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEOMICS;

EID: 84867508405     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-120880     Document Type: Article

References (116)

1. Selkoe DJ (2008) Biochemistry and molecular biol912 ogy of amyloid - protein and the mechanism of Alzheimer's disease. In Handbook of Clinical Neurol ogy Dementias, Duyckaerts C, Litvan I (Eds.). Elsevier, pp. 245-260.
2. Walsh DM, Selkoe DJ (2007) A beta oligomers - a decade of discovery. J Neurochem 101, 1172-1184.
3. Stefani M, Dobson CM (2003) Protein aggregation and aggregate toxicity: New insights into protein folding, misfolding diseases and biological evolution. J Mol Med (Berl) 81, 678-699.
4. Lee J, Culyba EK, Powers ET, Kelly JW (2011) Amyloid- forms fibrils by nucleated conformational conversion of oligomers. Nat Chem Biol 7, 602-609.
5. Roychaudhuri R, Yang M, Hoshi MM, Teplow DB (2009) Amyloid -protein assembly and Alzheimer disease. J Biol Chem 284, 4749-4753.
6. Harper JD, Lansbury J (1997) Models of amyloid seeding in Alzheimer's disease and scrapie: Mechanistic truths and physiological consequences of the time-dependent solubil-ity of amyloid proteins. Annu Rev Biochem 66, 385.
7. Tjernberg LO, Naslund J, Lindqvist F, Johansson J, Karl- strom AR, Thyberg J, Terenius L, Nordstedt C (1996) Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J Biol Chem 271, 8545-8548.
8. Lazo ND, Grant MA, Condron MC, Rigby AC, Teplow DB (2005) On the nucleation of amyloid -protein monomer folding. Prot Sci 14, 1581-1596.
9. Arimon M, Sanz F, Giralt E, Carulla N (2011) Template- assisted lateral growth of amyloid-42 fibrils studied by differential labeling with gold nanoparticles. Bioconjugate Chem 23, 27-32.
10. Kheterpal I, Williams A, Murphy C, Bledsoe B, Wetzel R (2001) Structural features of the Abeta amyloid fib-ril elucidated by limited proteolysis. Biochem 40, 11757- f11767.
11. Larson ME, Lesńe SE (2012) Soluble A- oligomer produc- tion and toxicity. J Neurochem 120, 125-139.
12. Tycko R (2011) Solid-state NMR studies of amyloid fibril structure. Annu Rev Phys Chem 62, 279-299.
13. Teplow DB, Lazo ND, Bitan G, Bernstein S, Wyttenbach T, Bowers MT, Baumketner A, Shea JE, Urbanc B, Cruz L, Borreguero J, Stanley HE (2006) Elucidating amyloid - protein folding and assembly:Amultidisciplinary approach. Accounts Chem Res 39, 635-645.
14. Streltsov VA, Varghese JN, Masters CL, Nuttall SD (2011) Crystal structure of the amyloid- p3 fragment provides a model for oligomer formation in Alzheimer's disease. J Neurosci 31, 1419-1426.
15. Hardy J, Selkoe DJ (2002) The Amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353.
16. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489.
17. Bitan G, Fradinger EA, Spring SM, TeplowDB (2005) Neu- rotoxic protein oligomers-what you see is not always what you get. Amyloid 12, 88-95.
18. Ferreira ST, Klein WL (2011) The A- oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol Learn Mem 96, 529-543.
19. Benilova I, Karran E, De Strooper B (2012) The toxic A- oligomer and Alzheimer's disease: An emperor in need of clothes. Nat Neurosci 15, 349-357.
20. Haupt C, Leppert J, R̈onicke R, Meinhardt J, Yadav JK, Ramachandran R, Ohlenschl̈ager O, Reymann KG, G̈orlach M, F̈andrich M (2012) Structural basis of -amyloid- dependent synaptic dysfunctions. Agnew Chem Int Ed Engl 51, 1576-1579.
21. Bitan G, Vollers SS, Teplow DB (2003) Elucidation of pri mary structure elements controlling early amyloid -protein oligomerization. J Biol Chem 278, 34882-34889.
22. Murray IVJ, Liu L,KomatsuH,UryuK,XiaoG, Lawson JA, Axelsen PH (2007) Membrane-mediated amyloidogenesis and the promotion of oxidative lipid damage by amyloid beta proteins. J Biol Chem 282, 9335-9345.
23. Kuo YM, EmmerlingMR,Woods AS, Cotter RJ, Roher AE 989 (1997) Isolation, chemical characterization, and quantitation 990 of A- 3-pyroglutamyl peptide from neuritic plaques and 991 vascular amyloid deposits. Biochem Biophys Res Commun 992 237, 188-191.
24. Kumar S, Singh S, Hinze D, Josten M, Sahl HG, Siep mannM,Walter J (2012) Phosphorylation of the amyloid- peptide at serine 8 attenuates its clearance via insulin degrad ing and angiotensin converting enzymes. J Biol Chem 287, 8641-8651.
25. Ono K, Condron MM, Teplow DB (2010) Effects of the English (H6R) andTottori (D7N) familialAlzheimer disease mutations on amyloid -protein assembly and toxicity. J Biol Chem 285, 23186-23197.
26. Fawver JN, Schall HE, Petrofes Chapa RD, Zhu X, Murray IVJ (2012) Amyloid- metabolite sensing: Bio chemical linking of glycation modification and misfolding. J Alzheimers Dis 30, 63-73.
27. Nilsberth C,Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, Stenh C, Luthman J, Teplow DB, Younkin SG, Naslund J, Lannfelt L (2001) The 'Arc tic' APP mutation (E693G) causes Alzheimer's disease by enhanced A- protofibril formation. Nat Neurosci 4, 887- 893.
28. Levy E, Carman MD, Fernandez-Madrid IJ, Power MD, Lieberburg I, van Duinen SG, Bots GT, LuyendijkW, Fran gioneB(1990)Mutation of theAlzheimer's disease amyloid gene in hereditary cerebral hemorrhage,Dutch type. Science 248, 1124-1126.
29. Hendriks L, van Duijn CM, Cras P, Cruts M, Van Hul W, van Harskamp F, Warren A, McInnis MG, Antonarakis SE, Martin JJ, Hofman A, Van Broeckhoven C (1992) Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the -amyloid precursor protein gene. Nat Genet 1, 218-221.
30. Bugiani O, Giaccone G, Rossi G, Mangieri M, Capobianco R, Morbin M, Mazzoleni G, Cupidi C, Marcon G, Gio vagnoli A, Bizzi A, Di Fede G, Puoti G, Carella F, Salmaggi A, Romorini A, Patruno GM, Magoni M, Padovani A, Tagliavini F (2010) Hereditary cerebral hemorrhage with amyloidosis associated with the E693K mutation of APP. Arch Neurol-Chicago 67, 987-995.
31. Grabowski TJ, Cho HS, Vonsattel JP, Rebeck GW, Green1031 berg SM (2001) Novel amyloid precursor protein mutation in an Iowa familywith dementia and severe cerebral amyloid angiopathy. Ann Neurol 49, 697-705.
32. Tomiyama T, Nagata T, Shimada H, Teraoka R, Fukushima A, Kanemitsu H, Takuma H, Kuwano R, ImagawaM, Ataka S, Wada Y, Yoshioka E, Nishizaki T, Watanabe Y, Mori H (2008) A new amyloid beta variant favoring oligomer ization in Alzheimer's-type dementia. Ann Neurol 63, 377-387.
33. Hung LW, Ciccotosto GD, Giannakis E, Tew DJ, Perez K, Masters CL, Cappai R, Wade JD, Barnham KJ 1042 (2008) Amyloid- peptide (A-) neurotoxicity is modu lated by the rate of peptide aggregation: A- dimers and trimers correlate with neurotoxicity. J Neurosci 28, 11950-5 11958.
34. Johansson A-S, Bergquist J, Volbracht C, Paivio A, Leist M, Lannfelt L, Westlind-Danielsson A (2007) Attenuated amyloid- aggregation and neurotoxicity owing to methio- nine oxidation. Neuroreport 18, 559-563.
35. Hou LM, Kang I, Marchant RE, Zagorski MG (2002) Methionine 35 oxidation reduces fibril assembly of the amy- loid A beta-(1-42) peptide of Alzheimer's disease. J Biol Chem 277, 40173-40176.
36. Maheshwari M, Roberts JK, DeSutter B, Duong KT, Tin-gling J, Fawver JN, Schall HE, Kahle M, Murray IV (2010) Hydralazine modifiesA- fibril formation and prevents mod-ification by lipids in vitro. Biochem 49, 10371-10380.
37. Scḧagger H, von Jagow G (1987) Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separa-tion of proteins in the range from 1 to 100 kDa. Anal Biochem 166, 368-379.
38. Giasson BI, Duda JE, Murray IVJ, Chen QP, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VMY (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290, 985-989.
39. Murray IVJ, Medford MA, Guan HP, Rueter SM, Tro-janowski JQ, Lee VMY (2003) Synphilin in normal human brains and in synucleinopathies: Studies with new antibod-ies. Acta Neuropathol 105, 177-184. 10700
40. Gervais F, Paquette J, Morissette C, Krzywkowski P, Yu M, Azzi M, Lacombe D, Kong X, Aman A, Laurin J, Szarek 1072 WA, Tremblay P (2007) Targeting soluble A- peptide with 1073 Tramiprosate for the treatment of brain amyloidosis. Neu-robiol Aging 28, 537-547. 10755
41. Necula M, Breydo L, Milton S, Kayed R, van der Veer WE, Tone P, Glabe CG (2007) Methylene blue Inhibits Amyloid 1077 A- oligomerization by promoting fibrillization. Biochem 1078 46, 8850-8860.
42. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy 1081 SA, Cole GM (2005) Curcumin inhibits formation of Amy-loid - oligomers and fibrils, binds plaques, and reduces 1083 amyloid in vivo. J Biol Chem 280, 5892-5901.
43. Williams AD, Sega M, Chen M, Kheterpal I, Geva M, Berthelier V, Kaleta DT, Cook KD, Wetzel R (2005) Structural properties of A- protofibrils stabilized by a small molecule. Proc Natl Acad Sci U S A 102, 7115-7120.
44. Sugita Y, Okamoto Y (1999) Replica-exchange molecular dynamics method for protein folding. Chem Physics Lett 314, 141-151.
45. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Sim- merling C (2006) Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 65, 712-725.
46. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA (2004) Development and testing of a general amber force field. J Comput Chem 25, 1157-1174.
47. Onufriev A, Bashford D, Case DA (2004) Exploring pro- tein native states and large-scale conformational changes with a modified generalized born model. Proteins 55, 383- 394.
48. Case DA, Darden TA, Cheatham TE, Simmerling CL,Wang J, Duke RE, Luo R, CrowleyM,Walker RC, ZhangW, Merz KM,Wang B, Hayik S, RoitbergA, Seabra G,Kolossvary L, Wong KF, Paesani F, Vanicek J, Wu X, Brozell SR, Stein- brecher T, Gohlke H, Yang L, Tan C, Mongon J, Hornak V, Gui C, Mathews DH, Seetin MJ, Babin V, Kollman PA (2008) Amber 10 University of California, San Franciscoo
49. Allen MP, Tildesley DJ (1989) Computer simulations of liquids, Clarendon Press, Oxford.
50. Frenkel D, Smit B (2002) Understanding molecular simula tion: From algorithms to applications, Academic Press, San Diego.
51. Patriksson A, van der Spoel D (2008) A temperature pre dictor for parallel tempering simulations. Phys Chem Chem Phys 10, 2073-2077
52. Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, Chong L, Lee M, Lee T, Duan Y, Wang W, Donini O, Cieplak P, 1121 Srinivasan J, Case DA, Cheatham TE (2000) Calculating structures and free energies of complexmolecules: Combin ing molecular mechanics and continuum models. Accounts Chem Res 33, 889-897.
53. Dupuis NF,Wu C, Shea JE, BowersMT (2009) Human islet amyloid polypeptide monomers form ordered -hairpins: A possible direct amyloidogenic precursor. J Am Chem Soc 131, 18283-18292.
54. CaseDA(1994)Normalmode analysis of protein dynamics. Curr Opin Struct Biol 4, 285-290.
55. KabschW, Sander C (1983)Dictionary of protein secondary structure: Pattern recognition of hydrogen-bonded and geo metrical features. Biopolymers 22, 2577-2637.
56. Wise-SciraO,Xu L,Kitahara T, PerryG,CoskunerO(2011) 1135 Amyloid- peptide structure in aqueous solution varieswith fragment size. J Chem Phys 135, 205101-205114.
57. ChenYR,GlabeCG(2006)Distinct early folding and aggre gation properties of Alzheimer amyloid- peptides A-40 1139 and A-42. J Biol Chem 281, 24414-24422.
58. Waxman E, Duda J, Giasson B (2008) Characterization of antibodies that selectively detect-synuclein in pathological inclusions. Acta Neuropathol 116, 37-46.
59. Bitan G (2006) Structural study of metastable amyloido genic protein oligomers by photo-induced cross-linking of unmodified proteins. Method Enzymol 413, 217-236.
60. O'Nuallain B, Shivaprasad S, Kheterpal I, Wetzel R (2005) Biochem 44, 12709-12718.
61. Cheng IH, Scearce-Levie K, Legleiter J, Palop JJ, Gerstein H, Bien-Ly N, Puoliväli J, Lesné S, Ashe KH, Muchowski PJ, Mucke L (2007) Accelerating amyloid- fibrilliza tion reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem 282, 23818-1154 23828.
62. Butterfield D, Sultana R (2011) Methionine-35 of A-(1-1156 42): Importance for oxidative stress in Alzheimer disease. J Amino Acids 2011, 198430.
63. Butterfield DA, Kanski J (2002) Methionine residue 35 is critical for the oxidative stress and neurotoxic properties of Alzheimer's amyloid beta-peptide 1-42. Peptides 23, 1161-1309.
64. Basi GS, Feinberg H, Oshidari F, Anderson J, Barbour R, 1163 Baker J,Comery TA,Diep L,GillD, Johnson-WoodK,Goel A, Grantcharova K, Lee M, Li J, Partridge A, Griswold-1165 Prenner I, Piot N, Walker D, Widom A, Pangalos MN, 1166 Seubert P, Jacobsen JS, Schenk D, Weis WI (2010) Struc1 tural correlates of antibodies associated with acute reversal of amyloid -related behavioral deficits in a mouse model of Alzheimer disease. J Biol Chem 285, 3417-3427.
65. Frenkel D, Balass M, Solomon B (1998) N-terminal EFRH sequence of Alzheimer's -amyloid peptide represents the epitope of its anti-aggregating antibodies. J Neuroimmunol 1173 88, 85-90.
66. Soto C, Castano EM, Frangione B, Inestrosa NC (1995) The -helical to -strand transition in the amino-terminal fragment of the amyloid -peptide modulates amyloid for-mation. J Biol Chem 270, 3063-3067. 11777
67. Cherny RA, Legg JT, McLean CA, Fairlie DP, Huang XD, Atwood CS, Beyreuther K, Tanzi RE, Masters CL, Bush AI (1999) Aqueous dissolution of Alzheimer's disease A beta amyloid deposits by biometal depletion. J Biol Chem 274, 23223-23228.
68. Mantyh PW, Ghilardi JR, Rogers S, DeMaster E, Allen CJ, Stimson ER, Maggio JE (1993) Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of beta-amyloid peptide. J Neurochem 61, 1171-1174.
69. LeVine H (2002) 4,4-dianilino-1,1-binaphthyl-5,5-disulfonate: Report on nonsheet conformers of Alzheimer's peptide (1-40). Arch Biochem Biophys 404, 106-115.
70. Ferrao-Gonzales AD, Robbs BK, Moreau VH, Ferreira A, Juliano L, Valente AP, Almeida FCL, Silva JL, Foguel D (2005) Controlling -amyloid oligomerization by the use of naphthalene sulfonates. J Biol Chem 280, 34747-34754.
71. Urbanc B, Cruz L, Yun S, Buldyrev SV, Bitan G, Teplow DB, Stanley HE (2004) In silico study of amyloid -protein folding and oligomerization. Proc Natl Acad Sci U S A 101, 17345-17350.
72. Paravastu AK, Leapman RD, Yau WM, Tycko R (2008) Molecular structural basis for polymorphism in Alzheimer's -amyloid fibrils. Proc Natl Acad Sci U S A 105, 18349-18354.
73. Petkova AT, Yau WM, Tycko R (2005) Experimental con-straints on quaternary structure in Alzheimer's -amyloid fibrils. Biochem 45, 498-512.
74. Kheterpal I, Chen M, Cook KD,Wetzel R (2006) Structural differences in A- amyloid protofibrils and fibrils mapped by hydrogen exchange - Mass spectrometry with on-line proteolytic fragmentation. J Mol Biol 361, 785-795.
75. Perchiacca JM, Ladiwala AR, Bhattacharya M, Tessier PM (2012) Structure-based design of conformation- and sequence-specific antibodies against amyloid -. Proc Natl Acad Sci U S A 109, 84-89.
76. Southwell AL, Patterson PH (2010) Antibody therapy in neurodegenerative disease. Rev Neurosci 21, 273-287.
77. Rahimi F, Bitan G (2010) Selection of aptamers for amyloid -protein, the causative agent of Alzheimer's disease. J Vis Exp 39, 1955.
78. Tsuji-Ueno S, Komatsu M, Takahashi M, Yoshino S, Suzuki M, Nemoto N, Nishigaki K (2011) Novel high-affinity A-binding peptides identified by an advanced in vitro evolution, progressive library method. Protein Peptide Lett 18, 642-650.
79. Sachse C, F̈andrich M, Grigorieff N (2008) Paired -sheet structure of an A-(1-40) amyloid fibril revealed by electron microscopy. Proc Natl Acad Sci U S A 105, 7462-7466.
80. Petkova AT, Ishii Y, Balbach JJ, Antzutkin ON, Leapman RD, Delaglio F, Tycko R (2002) A structural model for Alzheimer's -amyloid fibrils based on experimental con-straints from solid state NMR. Proc Natl Acad Sci U S A 99, 16742-16747.
81. Santa-Mar̀ia I, Herńáindez F, Moreno FJ,Avila J (2007)Tau-rine, an inducer for tau polymerization and a weak inhibitor for amyloid-peptide aggregation. Neurosci Lett 429, 91-94.
82. Herrmann N, Chau SA, Kircanski I, Lanct○ot KL (2011) Cur-rent and emerging drug treatment options for Alzheimer's disease: A systematic review. Drugs 71, 2031-2065.
83. Shaw JE, Chio J, Dasgupta S, Lai AY, Mo GCH, Pang F, Thomason LAM, Yang AJ, Yip CM, Nitz M, McLaurin J (2011)A- (1-42) assembly in the presence of scyllo-inositol derivatives: Identification of an oxime linkage as impor tant for the development of assembly inhibitors. ACS Chem Neurosci 3, 167-177.
84. Ono K, Hasegawa K, Naiki H, YamadaM(2004) Curcumin has potent anti-amyloidogenic effects for Alzheimer's -amyloid fibrils in vitro. J Neurosci Res 75, 742-750.
85. Kim H, Park BS, Lee KG, Choi CY, Jang SS, Kim YH, 1249 Lee SE (2005) Effects of naturally occurring compounds on fibril formation and oxidative stress of -amyloid. J Agric Food Chem 53, 8537-8541.
86. Caesar I, Jonson M, Nilsson KP, Thor S, Hammarström P (2012) Curcumin promotes A-beta fibrillation and reduces neurotoxicity in transgenic Drosophila. Plos ONE 7, e4.
87. Noormägi A, Primar K, Tougu V, Palumaa P (2012) Inter ference of low-molecular substances with the thioflavin-T fluorescence assay of amyloid fibrils. J Pept Sci 18, 59-64.
88. Hudson SA, Ecroyd H, Kee TW, Carver JA (2009) The thioflavin T fluorescence assay for amyloid fibril detection can be biased by the presence of exogenous compounds. FEBS J 276, 5960-5972.
89. LeVine H (1999) Quantification of -sheet amyloid fib ril structures with thioflavin T. Method Enzymol 309, 274-284.
90. Belkacemi A, Doggui S, Dao L, Ramassamy C (2011) Challenges associated with curcumin therapy in Alzheimer disease. Exp Rev Mol Med 13, e34-e49.
91. Zhang L, Fiala M, Cashman J, Sayre J, Espinosa A, Maha nian M, Zaghi J, Badmaev V, Graves MC, Bernard G, 1272 Rosenthal M (2006) Curcuminoids enhance amyloid-beta uptake by macrophages of Alzheimer's disease patients. J Alzheimers Dis 10, 1-7.
92. Vuddanda PR, Chakraborty S, Singh S (2010) Berberine: A potential phytochemical with multispectrum therapeutic activities. Expert Opin Invest Drugs 19, 1297-1307.
93. Kulkarni SK,DhirA(2010)Berberine:Aplant alkaloidwith therapeutic potential for central nervous system disorders. Phytother Res 24, 317-324.
94. Jiang H, Wang X, Huang L, Luo Z, Su T, Ding K, Li X (2011) Benzenediol-berberine hybrids: Multifunctional agents forAlzheimer's disease. BioorgMed Chem19, 7228-7235.
95. Katsuno M, Tanaka F, Sobue G (2012) Perspectives on molecular targeted therapies and clinical trials for neurodegenerative diseases. J Neurol Neurosurg Psychiatry 83, 329-335.
96. Leon WC, Canneva F, Partridge V, Allard S, Ferretti MT, DeWildeA,Vercauteren F,AtifehR,DucatenzeilerA,Klein W, SzyfM,AlhonenL, CuelloAC(2010)Anovel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment. J Alzheimers Dis 20, 113-126.
97. Ohyagi Y (2008) Intracellular amyloid beta-protein as a therapeutic target for treating Alzheimer's disease. Curr Alzheimers Res 5, 555-561.
98. Morgan D (2011) Immunotherapy for Alzheimer's disease. J Int Med 269, 54-63.
99. Hillen H, Barghorn S, Striebinger A, Labkovsky B, Müller R, Nimmrich V, Nolte MW, Perez-Cruz C, van der Auwera I, van Leuven F, van Gaalen M, Bespalov AY, Schoemaker H, Sullivan JP, Ebert U (2010) Generation and therapeutic efficacy of highly oligomer-specific -amyloid antibodies. J Neurosci 30, 10369-10379.
100. Lee EB, Leng LZ, Zhang B, Kwong L, Trojanowski JQ, Abel T, Lee VMY (2006) Targeting amyloid-beta pep-tide (A beta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in A beta precursor protein (APP) transgenic mice. J Biol Chem 281, 4292-4299.
101. Lambert MP, Viola KL, Chromy BA, Chang L, Mor-gan TE, Yu J, Venton DL, Krafft GA, Finch CE, Klein WL (2001) Vaccination with soluble A- oligomers gener-ates toxicity-neutralizing antibodies. J Neurochem 79, 595-605.
102. Puzzo D, Privitera L, Fa'M, Staniszewski A, Hashimoto G, Aziz F, Sakurai M, Ribe EM, Troy CM, Mercken M, Jung SS, Palmeri A, Arancio O (2011) Endogenous amyloid- is necessary for hippocampal synaptic plasticity and memory. Ann Neurol 69, 819-830.
103. Abramov E, Dolev I, Fogel H, Ciccotosto GD, Ruff E, Slut-sky I (2009) Amyloid- as a positive endogenous regulator of release probability at hippocampal synapses. Nat Neu-rosci 12, 1567-1576.
104. Maloney B, Lahiri DK (2011) The Alzheimer's amyloid -peptide (A-) binds a specific DNA A-interacting domain (A-ID) in the APP, BACE1, and APOE promoters in a sequence-specific manner: Characterizing a new regulatory motif. Gene 488, 1-12.
105. Ohyagi Y, Asahara H, Chui DH, Tsuruta Y, Sakae N, Miyoshi K, Yamada T, Kikuchi H, Taniwaki T, Murai H, Ikezoe K, Furuya H, Kawarabayashi T, Shoji M, Checler F, Iwaki T, Makifuchi T, Takeda K, Kira Ji, Tabira T (2005) Intracellular A-42 activates p53 promoter: A pathway to neurodegeneration in Alzheimer's disease.FASEBJ 19, 255-257.
106. Bailey JA, Maloney B, Ge YW, Lahiri DK (2011) Func-tional activity of the novel Alzheimer's amyloid -peptide interacting domain (A-ID) in the APP andBACE1 promoter sequences and implications in activating apoptotic genes and in amyloidogenesis. Gene 488, 13-22.
107. Roberts GW, Gentleman SM, Lynch A, Murray L, Landon M, Graham DI (1994) Beta amyloid protein deposition in the brain after severe head injury: Implications for the pathogen-esis of Alzheimer's disease. J Neurol Neurosurg Psychiatry 57, 419-425.
108. Uryu K, Giasson BI, Longhi L, Martinez D, Murray I, Conte V, Nakamura M, Saatman K, Talbot K, Horiguchi T, McIntosh T, Lee VMY, Trojanowski JQ (2003) Age-dependent synuclein pathology following traumatic brain injury in mice. Exp Neurol 184, 214-224.
109. Tsachaki M, Ghiso J, Efthimiopoulos S (2008) BRI2 as a central protein involved in neurodegeneration. Biotechnol J 3, 1548-1554.
110. O'Connor T, Sadleir KR, Maus E, Velliquette RA, Zhao J, Cole SL, Eimer WA, Hitt B, Bembinster LA, Lammich S, Lichtenthaler SF, H́ebert SS, De Strooper B, Haass C, Ben-nett DA, Vassar R (2008) Phosphorylation of the translation initiation factor eIF2a increases BACE1 levels and promotes amyloidogenesis. Neuron 60, 988-1009.
111. Uryu K, Chen XH, Martinez D, Browne KD, Johnson VE, Graham DI, Lee VMY, Trojanowski JQ, Smith DH (2007) Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans. Exp Neu-rol 208, 185-192.
112. Kokjohn TA, Maarouf CL, Roher AE (2011) Is Alzheimer's disease amyloidosis the result of a repair mechanism gone astray? Alzheimers Dement, doi: 10.1016/j.jalz.2011.05.2429.
113. Petrofes Chapa RD, Emery MA, Fawver JN, Murray IV (2012)Amyloids as Sensors and Protectors (ASAP) hypoth esis. J Alzheimers Dis 29, 503-514.
114. Hardy J, Cullen K (2006) Amyloid at the blood vessel wall. Nat Med 12, 756-757.
115. Hardy J (2007) Does A-42 have a function related to blood homeostasis? Neurochem Res 32, 833-835.
116. Moreno JA, Radford H, Peretti D, Steinert JR, Verity N, Martin MG, Halliday M, Morgan J, Dinsdale D, Ortori CA, Barrett DA, Tsaytler P, Bertolotti A, Willis AE, Bushell M, Mallucci GR (2012) Sustained translational repression by eIF2a-P mediates prion neurodegeneration. Nature 485, 507-511.